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Abstract 
RNA interference (RNAi) is a simple and powerful tool widely used to study gene 
functions in many species. Vector-based systems using RNA polymerase III promoters 
have been developed to achieve stable expression of small interfering RNA (siRNA) or 
small hairpin RNA (shRNA) in mammalian cells. Recent investigations demonstrated 
that when, combined with the Cre-loxP system, the vector based RNAi can be used to 
achieve conditional or tissue specific knockdown of endogenous genes with high 
efficiency in mice. Here, we review these recent progresses and discuss the advantages, 
limitations and future development of this emerging technology. 
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Introduction 
Since the publication of the first transgenic mice in 1980 [1], mouse genetics constitutes 
one of the primary fields to explore the consequence of manipulating gene expression. 
The transgenic approach and gene targeting (knockout) in mice make possible to modify 
any genes with various mutations, i.e. over expression, constitutive activation, loss of 
function, hypomorphic mutation, conditional and/or tissue specific inactivation [2-5]. 
Despite great efforts have been made to improve efficiency of these techniques, the 
manipulation of genes remains difficult and time-consuming. For example, the generation 
of a knockout or conditional knockout mouse requires years of work and sometimes does 
not yield to significant results. This accounts for one of the main reasons why the 
published knockouts represent only 10% of mouse genes of 30,000 [6]. On the other 
hand, generation of transgenic mice remains the quickest way to obtain results on the 
function of a specific gene, although it primarily gives information from over-
expression. Recently, many laboratories have developed various methods to 
knockdown gene expression using RNAi in mice . In this review, we will mainly 
discuss these recent progresses. Readers who are interesting in any other aspects of RNAi 
are referred to a number of other recent reviews [7-10]. 
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How RNAi works? 
RNA interference corresponds to a specific target mRNA degradation involving small 
perfectly homologous double-strand RNAs also called small interfering RNAs (siRNAs). 
This leads to a decrease (but not absence) of expression of the corresponding protein. 
This natural process has been discovered in 1998 in the invertebrate nematode 
Caenorhabditis elegans [11, 12]. Other studies have shown that RNAi is a common 
process encountered in unicellular protozoa’s, insects, fungi, but also plants and 
vertebrates [13]. Originally, RNAi has probably evolved to fight against viruses and 
transposable elements that include a double strand RNA step in their replication cycle 
[14]. It is also generally assumed that RNAi is involved in developmental processes in 
multicellular organisms and chromatin structure regulation [15, 16]. 
Basically, when a double strand RNA or an RNA containing an equivalent 
structure (generally due to homologous folding) is introduced or produced in a cell, a 
ribonuclease called Dicer recognizes this molecule and processes it into short double 
strand RNA of 21-base pairs (bp) containing 2-nucleotide 3’-overhangs. These 
molecules, called siRNAs, can also be easily introduced in any cells during transient 
transfection experiments. A multi-subunit complex called RISC (RNA-induced silencing 
complex) then binds one molecule of siRNAs (Fig. 1). Among its subunits, a helicase 
unwinds the siRNA and one of the strands is used as bait by a homology-searching 
component to catch an endogenous target mRNA bearing the same sequence. Upon 
binding, the mRNA is degraded by the RISC endonuclease and exonuclease subunits; a 
new cycle then begins. Thus, any mRNA bearing a homologous sequence with a siRNA 
is degraded and its expression is knocked down to 10-40% of its normal levels [17].  
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In addition to this linear mechanism, plants, worms and insects have developed an 
amplification loop with an additional enzyme complex called RdRp for RNA-dependent 
RNA polymerase [18]. The siRNA provides sequence-specific primers and the target 
mRNA is used as the template. The RdRp complex produces large quantities of siRNAs 
and then an additional defense mechanism. This alternate step does not exist in mammals 
[19-21]. 
RNA interference techniques have become widely used in numerous laboratories 
since Elbashir and al [22-24] first described efficient knockdown in transfected 
mammalian cells with in vitro synthesized siRNAs. Their size needs to be <22 base 
pairs. Longer siRNAs activate an interferon reaction, leading to a general inhibition 
of translation, rather than the desired specific knockdown [22-24]. However, an 
increasing number of publications using microarrays suggest that short siRNAs (<22 bp) 
might also induce non-specific knockdown [25-27]. On the other hand, a few studies 
demonstrated a very specific effect of one siRNA on a large scale [28-30]. One evoked 
reason for an eventual non-specific effect is a special interferon response for short siRNA 
[25, 27]. Another reason might be the huge quantity of small dsRNA that are transfected 
in each single cell. The development of sh (small hairpin) RNA-synthesizing vectors has 
allowed a better control of in vitro RNA interference. Indeed, several laboratories have 
developed new plasmids containing polymerase III promoters, like the ones of the U6 
and H1 genes, known to synthesize small RNA. Those vectors allow synthesis of 50 bp-
long single strand RNA that folded in 21-23 bp dsRNA with a small hairpin in the 
middle. These shRNAs lack a 5’ cap and a long polyadenylated tail [31-33]. 
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Alternatively, other vectors have been created that allow synthesis of two complementary 
short RNA duplexes forming then a siRNA [34, 35].  
These constructs have several advantages. First, they allow a smoother synthesis 
of shRNAs in the cell compared to the brutal transfection of numerous siRNA molecules. 
Secondly, the time of action of a shRNA lasts much longer than a siRNA does, as the 
shRNA vectors can be stably integrated into the genome of recipient cells [36]. 
Finally, expression of these vectors can be controlled by inducible elements to achieve 
temporal and spatial knockdown of genes of interest, which will be discussed further in 
this review.  
RNAi in mice 
RNA interference can be performed at the whole animal level. C. elegans and Drosophila 
can be easily manipulated by soaking the animals in a solution containing siRNAs or by 
adding bacteria expressing siRNAs to the diet [37, 38]. Significant and quick 
knockdown (72 hours after soaking) can be obtained with these procedures; 
however, they cannot be applied for mammals. 
RNAi mediated gene knockdown in mice has been performed throughout 
various techniques at multiple levels. siRNAs or long dsRNAs (>500 bp) synthesized 
by an oocyte-specific promoter (from a vector) have been injected into mouse oocytes 
and zygotes to study gene functions during embryonic development [21, 39]. The 
injected oocytes or embryos can be maintained in culture condition in a specific 
medium and their phenotypes and growth properties can be monitored. These 
studies showed that efficient knockdown of transgenic eGFP, endogenous c-Mos or E-
Cadherin could be achieved. We have mentioned earlier that long dsRNA might 
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generated a non-specific response due to their length; however, it appears that, in oocytes, 
they do not activate the same pathways previously described in somatic cells. Thus, this 
technique looks suitable to study early development of the embryos. 
Taken advantage of the dominant nature of the RNAi, embryonic stem (ES) cells 
carrying stably integrated shRNAi vectors were also used to generate embryos by 
tetraploid aggregation method [40, 41]. Because the tetraploid embryos can only form 
the placenta and the yolk sac in the fusion embryos owing to their increased ploidy, 
the entire embryo proper is ES cells derived. In one of the study, the authors showed 
that strong expression of an shRNA targeting RasGAP, a p120-RAS GTPase-
activating protein, impaired normal development at embryonic day 9.5. Severity of 
the phenotype was concordant with the levels of shRNA knockdown [40]. The 
delivery has also been improved by the use of various adeno-, lenti- or retrovirus to 
increase transfection efficiency [42, 43]. All those experiments have shown efficient 
knockdown of exogenous or endogenous genes like p53, Bim, CD25 or CD8α . 
Additionally, Hemann and co-workers introduced hematopoietic stem cells expressing 
p53-targeting shRNA into irradiated mice and observed several kinds of phenotypes in 
reconstituted organs, which were correlated with the shRNA expression levels [44]. All 
those experiments show that RNAi could be performed in mice at the cellular or 
embryonic level. 
To target an adult mice, shRNAs or siRNAs has been administrated using a 
method called “tail vein injection” (or “hydrodynamic transfection method”), which had 
been widely used before to allow expression of a variety of plasmids in the liver [45-47]. 
Basically, a solution of DNA (ranging from 10-500 µg desolved in 2.5 mL of Ringer’s 
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solutions) is injected into recipient mice through tail vein with a 27-gauge needle. 
The levels of transgene expression depend on the volume and injection rate. Under 
slow conditions of injection, the DNA enters the blood stream and is rapidly 
degraded by the blood nucleases. The “high-pressure” delivery leads to the 
accumulation of the DNA solution in the inferior vena cava; indeed the injected 
volume is almost equal to the blood volume and the cardiac output is overflown by 
the rapid delivery of the DNA solution. The resulting high pressure surrounding the 
liver allows the “DNA transfection” into the parenchyma. Toxicity studies show that 
most animals recover well from the procedure [45]. Expression of a gene coding by 
the DNA can be observed within the first 24 hours and approximately 50% of 
hepatocytes express the transgene [45, 47]. In addition, several laboratories have 
shown that it was also possible to deliver naked plasmid DNA to various tissues (i.e. 
muscle and liver) through direct injection into the tissue or into the vessels 
surrounding the organ (portal vein, hepatic vein or bile duct for the liver) [47].  
Lewis et al (2002) were the first to knockdown transgenic eGFP expression using 
RNAi in mice using the hydrodynamic transfection method [48]. Human viral RNAs 
(Hepatitis B and C) have also been targeted by other laboratories using the same 
procedure [49-51]. More recently, Song and colleagues performed a similar experiment 
on the Fas gene, a protein sometimes involved in autoimmune hepatic diseases, and 
protected the mice against fulminant hepatitis [52]. Those experiments have shown that 
the liver could be easily targeted to disrupt functions of exogenous, or endogenous genes. 
Unfortunately, this could be obtained mainly in the liver and only for a short period of 
time (around 1 week). Repeated injections must be performed to reach an efficient 
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knockdown effect [48]. The use of cationic liposome has shown that it was possible to 
target other organs in addition to the liver with a GFP-based RNAi experiment [53]. The 
protocol is closed to the ones used commonly for transient transfection experiments 
at the cell culture level: a cationic lipid is complexed with siRNA and plasmid DNA 
coding the target mRNA. Equivalent knockdown of eGFP expression in the liver 
and the spleen was observed 72h after intravenous administration of the siRNA 
specific to eGFP. In the same study, the authors also demonstrated that the 
intraperitoneal injected siRNA specific for TNFα  favored development of sepsis in 
liposaccharide-treated mice [53]. 
Most notably, Hasuwa and colleagues (2002) used a transgenic approach by 
directly injecting an shRNA construct against eGFP to the pronucleus of zygotes [54]. 
The transgenic mice were then crossed with mice that ubiquitously express the eGFP 
gene. Their data demonstrated that expression of the eGFP siRNA efficiently silenced the 
eGFP gene in every part of the mouse analyzed. This study proves in principle that 
shRNA can knockdown genes in mice.  
 
Inducible RNAi in mice 
Our review of literature thus far has revealed the feasibility of RNAi-mediated gene 
knockdown in mice with high efficiency. However, with a threat of knockdown-induced 
lethality, new strategies have taken in account the possibility to generate inducible or 
tissue restricted models. These models in theory can bypass embryonic lethality and 
allow the study of specific genes in specific tissues. Several approaches have been 
developed in cultured cells, including tetracycline-inducible shRNA, ecdysone-
Coumoul and Deng 10
responsive system, and tamoxifen-induced Cre/loxP recombination system [30, 32, 55-
59]. 
Although all these approaches are promising, so far only Cre/loxP mediated RNAi 
has been reported to knockdown endogenous genes in mice. Two studies used lentivirus 
based RNAi systems, in which shRNA expression is controlled by a lox-stop-lox 
element. Because the stopper is placed between the TATA-box and the transcription start 
site of the U6 promoter, the shRNA cannot be expressed until it (lox-stop-lox element) 
is deleted by Cre-mediated excision [60, 61]. The third study by our group used a 
plasmid-based strategy [32, 33]. Our data demonstrated that the plasmid-based RNAi 
system is both simple and easy to use, and works with high efficiency in silencing 
expression of endogenous genes.  
In this approach, a neomycin cassette was inserted in the U6 RNA polymerase III 
promoter to disrupt its activity. The neo gene not only functions as a stopper but also 
serves as a selection marker when the shRNA construct is used in cell culture 
system. The neomycin cassette is flanked by loxP sites and can be deleted through the 
Cre/loxP mediated recombination [5]. After checking the efficiency of the system at the 
tissue culture level on two endogenous genes, Fgfr2 and Survivin, we found that the U6 
activity can be completely restored upon the excision of the neo by Cre/loxP mediated 
recombination [32]. We then decided to generate mice bearing our Fgfr2-targeting 
construct (U6-ploxPneo-Fgfr2) to test its in vivo efficiency. FGFR2 is one of the four 
high affinity FGF receptors that mediate the signaling of, at least, 22 FGF ligands [62]. In 
humans, missense mutations of FGFR2 have been related to craniosynostosis and limb 
abnormalities [62]. Fgfr2 also plays an important role in embryonic development and 
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organogenesis [62]. Consistent with our in vitro study showing that the presence of the 
neo inhibits the U6 promoter activity, transgenic mice bearing the U6-ploxPneo-Fgfr2 
shRNA construct showed no abnormalities. When crossed with EIIa-Cre transgenic 
mice, which express Cre in the mouse germline [63], ploxPneo is excised leading to 
activation of the U6 promoter and FGFR2-shRNA synthesis (Fig. 2A,B). We next 
determined levels of Fgfr2 expression by RT-PCR and found that all U6-Fgfr2;EIIa-Cre 
embryos exhibited dramatically reduced Fgfr2 transcripts while no obvious alteration 
was observed in all control embryos (Fig. 2C). Our analysis also revealed that U6-Fgfr2 
RNAi-mediated suppression is specific to Fgfr2 but not to any other family members 
(Fig. 2C). Next, we performed realtime-PCR analysis and were able to confirm dramatic 
downregulation of Fgfr2 transcripts in the U6-Fgfr2;EIIa-Cre, but not in any other 
control embryos (Fig. 3B).  
Previous studies showed that Fgfr2 mutant embryos generated by gene targeting 
died during embryonic stages [64-66]. Consistently, we found that a majority of U6-
Fgfr2;EIIa-Cre embryos died at middle gestation (Fig. 3A). On the other hand, when 
crossed with a transgenic strain that expresses Cre in the progress zone of the limb [67], 
embryos reach birth but with associated limbs and digits abnormalities (Fig. 3B), 
demonstrating in principle that the combination of the Cre/loxP and RNAi approaches 
can be used to decipher gene function in a tissue specific manner.    
Advantages, limitations, and perspectives 
Most RNAi experiments performed in mice have been compared with counterpart 
recombination knockout studies and most of them have revealed similar phenotypes [21, 
33, 39, 40, 60, 61]. However, RNAi knockdown in mice may have several advantages. 
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Currently, knockouts studies represent only 10% of total mouse genes [6]. Generation of 
transgenic mice carrying RNAi construct is fast; in our hands, we were able to produce 
several pure carriers in only 3 months (the time schedule to produce regular transgenic 
mice) compared to 12-24 months for conditional gene knockouts. Moreover, because 
RNAi acts dominantly, only one allele of transgene is needed to suppress the endogenous 
target gene, it reduces the time needed for breeding together two mutant alleles required 
by conditional knockout of genes with recessive nature. This advantage becomes more 
obvious when genetic interaction of two or more genes is studied [64, 68]. Thus, 
compared with the gene targeting technique, RNAi approach is both fast and simple, and 
therefore should be widely accessible. In this aspect, the existence of a large collection of 
Cre transgenic lines (hhttp://www.mshri.on.ca/nagy/cre-pub.html) should make it 
possible to have a quick assessment of RNAi-mediated gene knockdown in the tissue 
specific fashion. 
On the other hand, RNAi-mediated gene knockdown cannot replace gene 
targeting because expression of endogenous genes is not completely repressed. Instead, it 
should be used as a complement approach to study functions of genes, especially to those 
whose absence results in embryonic or early postnatal lethality. Generation of mice 
carrying mild phenotypes or various hypomorphic alleles could greatly facilitate studies 
in many fields of biological sciences. For example, knockout DNMT1 is lethal but only 
10% expression is enough for a mouse to survive. On the other hand, those mice have a 
clear phenotype, given information on the gene function [69]. Such level of down-
regulation is clearly in the range of an RNAi experiment.  
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Those advantages must not hide the limits of this new technique: among them, 
insertion of transgenes is still a matter of random in the genome. Then, the RNAi 
construct will always be dependant of the so-called positional variegation [70]. It was 
recently reported that the position effect could be minimized or overcome using an 
insulator [71]. Alternatively, RNAi construct can be targeted in the ES cells to a site that 
allow ubiquitous expression of the exogenous genes, such as Rosa-26 locus [72]. In 
addition, non-specific knockdown might be the biggest challenge for RNAi in vivo 
experiments. This problem might be solved by a careful selection of the RNAi sequences. 
Target structure, base composition and internal thermodynamic stability are 
important parameters to design a siRNA. The design of the siRNA or shRNA 
remains crucial and carefully accomplished [73]. Useful web sites for the design of 
effective si/shRNAs can be found in a recent review [74]. Using different shRNA or 
siRNA targeting the same gene has also been suggested to overcome this problem [44]. 
Finally, creating a transgenic line, although faster than the knockout strategy, is still 
time consuming. It is still appropriate to first assess the efficiency of the construct or 
the siRNA in transient transfection experiment in cell culture. New approaches for 
mammalian systems might have also been developed that used type II promoters 
and RNA polymerase II; two recent papers mentioned such techniques that appear 
to be more effective than the now traditional shRNA option and that could also be 
tightly regulated [75, 76]. 
Because shRNA constructs can be injected into the pronucleus of fertilized eggs, 
it can be applied to many other species where ES cells have not been established. A 
successful example has been reported in rat [54]. With the continuous increased 
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efficiency RNA interference and improved delivery in vivo, it is conceivable to imagine 
new human therapeutics involving controllable RNAi constructs to knockdown 
expression of alleles carrying missence mutations commonly seen in numerous forms of 
genetic diseases, such as those occurred in FGF receptors [62, 77]. 
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Figure legends 
Figure 1. An overview of RNA interference. See text for explanations. 
 
Figure 2. Cre mediated deletion of the neo  from U6-ploxPneo-Fgfr2 transgene 
knockdown Fgfr2 transcripts. (A) Structure of U6-ploxPneo-Fgfr2 transgene prior to and 
after deletion of ploxPneo. (B) Northern blot analysis showing that U6-Fgfr2 transgene is 
only expressed in U6-Fgfr2;EIIa-Cre embryos, as evidenced by the presence of 86 
nucleotides transcription product. Equal RNA loading was assessed by ethidium bromide 
staining of the upper portion of the gel (lower). (C) RT-PCR analysis of Fgfr1-4 
expression in embryos of different genotypes. Wt: Wild type; U6: U6-ploxPneo-Fgfr2; 
Cre: EIIa-Cre; and U6;Cre: U6-Fgfr2;EIIa-Cre. The first row is a longer exposure of the 
second row. All samples are from E12.5 embryos. 
 
Figure 3. Phenotypes associated with Fgfr2 knockdown mediated by RNAi. (A) E11.5 
U6-Fgfr2;EIIa-Cre and wild type embryos, showing that knockdown of Fgfr2 from 
germline results in embryonic lethality. (B) P19 U6-Fgfr2;AP2-Cre and wild type mice. 
showing abnormal limbs (arrow) in the mutant mice. 
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